Advertisement

Rheumatology International

, Volume 29, Issue 1, pp 53–57 | Cite as

Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial

  • H. Al-Rayes
  • R. Al-Swailem
  • M. Al-Balawi
  • N. Al-Dohayan
  • S. Al-Zaidi
  • M. TariqEmail author
Original Article

Abstract

In this open-label trial, ten male patients with active Behcet’s uveitis were enrolled. Initially, two infliximab infusions (5 mg/kg) were given at weeks 0 and 2. The patients continued to receive conventional therapy on recurrence of severe uveitis (RSU) attack. The patients with further attack were regularly given infliximab infusions every 8 weeks. In cases of further RSU attacks, the infusion interval was reduced to 6 weeks. The total follow-up period was 3 years. The patients were monitored for RSU, visual acuity and adverse effects. Reduction in the doses of prednisolone was also monitored. After receiving two infliximab infusions at weeks 0 and 2, three patients remained attack-free and seven patients had another RSU attack between 8th and 47th week. These patients were regularly given infliximab at 8-week intervals. Five out of seven patients remained attack-free. In two patients who had further attack, infusion frequency was increased to 6 weeks. There was a remarkable improvement in visual acuity with no significant adverse reaction except mild respiratory tract infection (two patients), headache (one patient) and mild infusion reaction (one patient). Infliximab is a safe and effective drug for the management of Behcet’s uveitis. Selection of optimal dose and frequency of infusion required standardization for individual patient.

Keywords

Behcet’s disease Uveitis Antitumor necrosis Factor-α antibody 

References

  1. 1.
    International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080Google Scholar
  2. 2.
    Tugal-Tutkun J, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behcet’s disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380PubMedCrossRefGoogle Scholar
  3. 3.
    Atmaca LS, Batioglu F (1994) The efficacy of cyclosporine-A in the treatment of Behcet’s disease. Ophthalmic Surg 25:321–327PubMedGoogle Scholar
  4. 4.
    Ozdal PC, Ortac S, Taskintuna I, Firat E (2002) Long-term therapy with low dose cyclosporine A in ocular Behcet’s disease. Doc Ophthalmol 105:301–312PubMedCrossRefGoogle Scholar
  5. 5.
    Kaklamani VG, Kaklamani PG (2001) Treatment of Behcet’s disease: an update. Semin Arthritis Rheum 30:299–312PubMedCrossRefGoogle Scholar
  6. 6.
    Hamzaoui K, Hamza M, Ayed K (1990) Production of TNF-alpha and IL-1 in active Behcet’s disease. J Rheumatol 17:1428–1429PubMedGoogle Scholar
  7. 7.
    Santos LM, Marcos MC, Gallardo Galera JM (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33:251–255CrossRefGoogle Scholar
  8. 8.
    Gul A (2001) Behcet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 19(Suppl 24):S6–S12PubMedGoogle Scholar
  9. 9.
    Maini SR (2004) Infliximab treatment of rheumatoid arthritis. Rheum Dis Clin North Am 30:329–347PubMedCrossRefGoogle Scholar
  10. 10.
    Rutgeerts P, van Assche G, Vermeire S (2004) Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126:1593–1610PubMedCrossRefGoogle Scholar
  11. 11.
    Braun J, Sieper J (2004) Biological therapies in the spondyloarthritides: the current state. Rheumatology (Oxford) 43:1072–1084CrossRefGoogle Scholar
  12. 12.
    Haugeberg G, Velken M, Johnsen V (2000) Successful treatment of genital ulcers with infliximab in Behcet’s disease. Ann Rheum Dis 63:744–745CrossRefGoogle Scholar
  13. 13.
    Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gul A (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behcet’s disease: an open-label trial. Arthritis Rheum 52:2478–2484PubMedCrossRefGoogle Scholar
  14. 14.
    Andonopoulos AP, Meimaris N, Daoussis D et al (2003) Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behcet’s disease. Clin Exp Rheumatol 21(Suppl 30):S57–S58PubMedGoogle Scholar
  15. 15.
    Kram MT, May LD, Goodman S, Molinas S (2003) Behcet’s Ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 46:118–121PubMedCrossRefGoogle Scholar
  16. 16.
    Sfikakis PP, Kaklamanis PH, Elezoglou A et al (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet’s disease. Ann Intern Med 140:404–406PubMedGoogle Scholar
  17. 17.
    Nakamura S, Ohno S (2005) Anti-tumor necrosis factor alpha antibody in the treatment of Behcet’s disease. Int Ophthalmol Clin 45:179–189PubMedCrossRefGoogle Scholar
  18. 18.
    Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet 358:295–296PubMedCrossRefGoogle Scholar
  19. 19.
    Kaklamani VG, Kaklamanis PG (2001) Treatment of Behcet’s disease: an update. Semin Arthritis Rheum 30:299–312PubMedCrossRefGoogle Scholar
  20. 20.
    Carmaschi P, Biasi D, Lombathi M et al (2006) Anti-TNF therapy in rheumatoid arthritis and autoimmunity. Rheum Int 26:209–214CrossRefGoogle Scholar
  21. 21.
    Comby E, Tanaff P, Mariotte D et al (2006) Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with long term infliximab therapy. J Rheum 33:24–30PubMedGoogle Scholar
  22. 22.
    Louis M, Rauch J, Armstrong M, Fitzcharles MA (2003) Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 30:2557–2562PubMedGoogle Scholar
  23. 23.
    Weill B, Kahan A (2004) Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 22:756–758PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • H. Al-Rayes
    • 1
  • R. Al-Swailem
    • 1
  • M. Al-Balawi
    • 1
  • N. Al-Dohayan
    • 2
  • S. Al-Zaidi
    • 1
  • M. Tariq
    • 3
    Email author
  1. 1.Department of MedicineRiyadh Military HospitalRiyadhSaudi Arabia
  2. 2.Department of OphthalmologyRiyadh Military HospitalRiyadhSaudi Arabia
  3. 3.Department of Medical ResearchRiyadh Military HospitalRiyadhSaudi Arabia

Personalised recommendations